vs
Side-by-side financial comparison of ALLEGRO MICROSYSTEMS, INC. (ALGM) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $229.2M, roughly 1.4× ALLEGRO MICROSYSTEMS, INC.). Bio-Techne runs the higher net margin — 16.4% vs 3.6%, a 12.7% gap on every dollar of revenue. On growth, ALLEGRO MICROSYSTEMS, INC. posted the faster year-over-year revenue change (28.9% vs -1.5%). Over the past eight quarters, ALLEGRO MICROSYSTEMS, INC.'s revenue compounded faster (17.2% CAGR vs 1.3%).
Allegro MicroSystems, Inc. is a global semiconductor firm designing and manufacturing high-performance power and sensing integrated circuits. Its core products include magnetic sensors, power ICs, and motion control solutions, serving automotive, industrial, consumer electronics, and communications markets worldwide.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ALGM vs TECH — Head-to-Head
Income Statement — Q2 FY2027 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $229.2M | $311.4M |
| Net Profit | $8.4M | $51.0M |
| Gross Margin | 46.7% | 66.9% |
| Operating Margin | 57.5% | 24.2% |
| Net Margin | 3.6% | 16.4% |
| Revenue YoY | 28.9% | -1.5% |
| Net Profit YoY | 369.0% | 126.0% |
| EPS (diluted) | $0.04 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 26 | $229.2M | — | ||
| Q1 26 | — | $311.4M | ||
| Q4 25 | $229.2M | $295.9M | ||
| Q3 25 | $214.3M | — | ||
| Q2 25 | $203.4M | $317.0M | ||
| Q1 25 | $192.8M | $316.2M | ||
| Q4 24 | $177.9M | $297.0M | ||
| Q3 24 | $187.4M | $289.5M |
| Q3 26 | $8.4M | — | ||
| Q1 26 | — | $51.0M | ||
| Q4 25 | $8.3M | $38.0M | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | $-13.2M | $-17.7M | ||
| Q1 25 | $-14.8M | $22.6M | ||
| Q4 24 | $-6.9M | $34.9M | ||
| Q3 24 | $-33.7M | $33.6M |
| Q3 26 | 46.7% | — | ||
| Q1 26 | — | 66.9% | ||
| Q4 25 | 46.7% | 64.6% | ||
| Q3 25 | 46.3% | — | ||
| Q2 25 | 44.9% | 62.7% | ||
| Q1 25 | 41.4% | 67.9% | ||
| Q4 24 | 45.7% | 65.3% | ||
| Q3 24 | 45.7% | 63.2% |
| Q3 26 | 57.5% | — | ||
| Q1 26 | — | 24.2% | ||
| Q4 25 | 4.2% | 18.4% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | -1.3% | -7.5% | ||
| Q1 25 | -6.8% | 12.2% | ||
| Q4 24 | -0.0% | 16.0% | ||
| Q3 24 | 2.2% | 13.8% |
| Q3 26 | 3.6% | — | ||
| Q1 26 | — | 16.4% | ||
| Q4 25 | 3.6% | 12.8% | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | -6.5% | -5.6% | ||
| Q1 25 | -7.7% | 7.1% | ||
| Q4 24 | -3.9% | 11.7% | ||
| Q3 24 | -18.0% | 11.6% |
| Q3 26 | $0.04 | — | ||
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.04 | $0.24 | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.07 | $-0.11 | ||
| Q1 25 | $-0.08 | $0.14 | ||
| Q4 24 | $-0.04 | $0.22 | ||
| Q3 24 | $-0.18 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $155.2M | $209.8M |
| Total DebtLower is stronger | $287.7M | — |
| Stockholders' EquityBook value | — | $2.1B |
| Total Assets | $1.4B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | $155.2M | — | ||
| Q1 26 | — | $209.8M | ||
| Q4 25 | $155.2M | $172.9M | ||
| Q3 25 | $117.5M | — | ||
| Q2 25 | $129.1M | $162.2M | ||
| Q1 25 | $121.3M | $140.7M | ||
| Q4 24 | $138.5M | $177.5M | ||
| Q3 24 | $188.8M | $187.5M |
| Q3 26 | $287.7M | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $280.7M | $260.0M | ||
| Q3 25 | $280.4M | — | ||
| Q2 25 | $304.8M | $346.0M | ||
| Q1 25 | $338.9M | $330.0M | ||
| Q4 24 | $368.7M | $300.0M | ||
| Q3 24 | $393.0M | $300.0M |
| Q3 26 | — | — | ||
| Q1 26 | — | $2.1B | ||
| Q4 25 | $962.7M | $2.0B | ||
| Q3 25 | $944.2M | — | ||
| Q2 25 | $922.7M | $1.9B | ||
| Q1 25 | $929.6M | $2.0B | ||
| Q4 24 | $933.0M | $2.1B | ||
| Q3 24 | $937.3M | $2.1B |
| Q3 26 | $1.4B | — | ||
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.4B | $2.7B | ||
| Q3 24 | $1.5B | $2.7B |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.29× | 0.13× | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.33× | 0.18× | ||
| Q1 25 | 0.36× | 0.16× | ||
| Q4 24 | 0.40× | 0.14× | ||
| Q3 24 | 0.42× | 0.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALGM
| Automotive | $164.5M | 72% |
| Industrial and Other | $64.7M | 28% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
